Lisa Smart

Dr. Lisa Smart

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2018 in Inflammation
Verified
Journal Article
Closed access
PDF file
LSLisa Smart
Lisa Smart
CBCorrin John Boyd
Corrin John Boyd
MCMelissa Anne Claus
Melissa Anne Claus
EBE. Bosio
E. Bosio
GHG. Hosgood
G. Hosgood
ARA. Raisis
A. Raisis

1 October 2018 in Journal of Critical Care
Verified
Journal Article
Closed access
LSLisa Smart
Lisa Smart
EBErika Bosio
Erika Bosio
SMStephen Macdonald
Stephen Macdonald
RDRandal Dull
Randal Dull
DFDaniel M. Fatovich
Daniel M. Fatovich
GAGlenn Arendts
Glenn Arendts

1 December 2017 in Journal of Critical Care
Verified
Journal Article
Closed access
LSLisa Smart
Lisa Smart
SMStephen Macdonald
Stephen Macdonald
SBSally Burrows
Sally Burrows
EBErika Bosio
Erika Bosio
GAGlenn Arendts
Glenn Arendts
DFDaniel M. Fatovich
Daniel M. Fatovich

7 October 2009 in Journal of Veterinary Emergency and Critical Care
Verified
Journal Article
Closed access
PDF file
LSLisa Smart
Lisa Smart
KJKarl E. Jandrey
Karl E. Jandrey
PKPhilip H. Kass
Philip H. Kass
JWJanelle R. Wierenga
Janelle R. Wierenga
FTFern Tablin
Fern Tablin

30 October 2012 in Journal of Veterinary Emergency and Critical Care
Verified
Journal Article
Closed access
PDF file
MHMark Haworth
Mark Haworth
LSLisa Smart
Lisa Smart

29 August 2017 in Trials
Verified
Journal Article
Open access
PDF file
SMStephen Macdonald
Stephen Macdonald
DTDavid McD Taylor
David McD Taylor
GKGerben Keijzers
Gerben Keijzers
GAGlenn Arendts
Glenn Arendts
DFDaniel M. Fatovich
Daniel M. Fatovich
BWBradley Wibrow
Bradley Wibrow
Guidelines recommend an initial intravenous (IV) fluid bolus of 30 ml/kg isotonic crystalloid for patients with sepsis and hypotension. However, there is a lack of evidence from clinical trials to support this. Accumulating observational data suggest harm associated with the injudicious use of fluids in sepsis. There is currently equipoise regarding liberal or restricted fluid-volume resuscitation as first-line treatment for sepsis-related hypotension. A randomised trial comparing these two approaches is, therefore, justified. The REstricted Fluid REsuscitation in Sepsis-associated Hypotension trial (REFRESH) is a multicentre, open-label, randomised, phase II clinical feasibility trial. Participants will be patients presenting to the emergency departments of Australian metropolitan hospitals with suspected sepsis and a systolic blood pressure of < 100 mmHg, persisting after a 1000-ml fluid bolus with isotonic crystalloid. Participants will be randomised to either a second 1000-ml fluid bolus (standard care) or maintenance rate fluid only, with the early commencement of a vasopressor infusion to maintain a mean arterial pressure of > 65 mmHg, if required (restricted fluid). All will receive further protocolised fluid boluses (500 ml or 250 ml, respectively), if required during the 6-h study period. The primary outcome measure is total volume administered in the first 6 h. Secondary outcomes include fluid volume at 24 h, organ support ‘free days’ to day 28, 90-day mortality, and a range of feasibility and process-of-care measures. Participants will also undergo serial measurement, over the first 24 h, of biomarkers of inflammation, endothelial cell activation and glycocalyx degradation for comparison between the groups. This is the first randomised trial examining fluid volume for initial resuscitation in septic shock in an industrialised country. A pragmatic, open-label design will establish the feasibility of undertaking a large, international, multicentre trial with sufficient power to assess clinical outcomes. The embedded biomarker study aims to provide mechanistic plausibility for a larger trial by defining the effects of fluid volume on markers of systemic inflammation and the vascular endothelium. Australia and New Zealand Clinical Trials Registry, ID: ACTRN12616000006448. Registered on 12 January 2016.